Highest-materiality recent filing
Zivo Bioscience to voluntarily deregister, cease SEC reporting; CFO and director resign
CFO William Sullivan resigns effective March 30, 2026; board member Alison Cornell resigns immediately as part of cost-cutting measures.
CFO Keith Marchiando resigns; William Sullivan appointed Interim CFO
Keith Marchiando resigns as CFO effective Dec 31, 2025; receives $27,040/mo through Dec 31, 2026.
Zivo Bioscience raises $250k initial tranche in $2M convertible debt offering
Issued $250k bridge promissory note with 10% annual interest, compounded annually; due after 2 years or upon $5M+ equity financing.
Zivo Bioscience issues 191,698 shares, raises ~$1.5M from accredited investor since Nov 2024
Sold 75,000 shares at $20.19 each to one accredited investor, gross proceeds ~$1.5M.
Adopted 2024 Director Equity Plan (875k shares, auto-increase 5%/yr). Director cash fee raised from $40k to $50k, eligible for restricted stock/RSUs.
Nasdaq formally delists Zivo Bioscience common stock and warrants
Nasdaq announced formal delisting on Feb 13, 2024; will file Form 25 with SEC.
ZIVO Bioscience receives Nasdaq delisting notice; shares to trade on OTC Pink Sheets
Nasdaq notified ZIVO on Nov 22, 2023 of delisting for noncompliance with Listing Rule 5550(b)(1).
Zivo Bioscience effects 1-for-6 reverse stock split to regain Nasdaq compliance
1-for-6 reverse split effective 5:00 p.m. ET Oct 26, 2023; trading split-adjusted Oct 27.
Zivo Bioscience granted Nasdaq extension to Nov 20, 2023 to regain equity compliance
Received deficiency notice on May 23, 2023 for stockholders' equity below $2.5M (Listing Rule 5550(b)).
Zivo Bioscience receives Nasdaq delisting notice for $2.5M equity non-compliance
Nasdaq notified Zivo on May 23, 2023 that it fails to meet $2.5M stockholders' equity requirement (Listing Rule 5550(b)).
Zivo Bioscience receives $1M bridge loan from CEO John Payne with 10% interest and warrants
CEO John Payne provides $1M unsecured six-month loan at 10% simple interest, extendable six months.
Zivo Bioscience receives Nasdaq delisting notice for insufficient equity
Nasdaq notified Zivo on Nov 22, 2022 of non-compliance with minimum $2.5M stockholders' equity requirement.
Zivo Bioscience receives USDA CVB jurisdiction for coccidiosis biologic; new study in Sept 2022
USDA CVB affirms jurisdiction over novel immune-modulating biologic for coccidiosis in broilers, removing regulatory ambiguity.
Submitted white paper to USDA for poultry coccidiosis product; expects jurisdiction confirmation within 8 weeks.
Zivo Bioscience restates Q3 2021 financials; delays 2021 10-K filing
Error in accounting for License Co-Development Participation Agreements; restates net loss for Q3 2021 from -$1.93M to -$1.58M.
Zivo reaffirms former CEO Andrew Dahl was terminated for cause, disputes his email claims
Company states Board terminated Andrew Dahl for cause; he was offered chance to resign before termination.
Zivo Bioscience terminates CEO Andrew Dahl for cause; Dahl resigns from board
CEO Andrew A. Dahl terminated for cause on Jan 4, 2022 after declining to resign; no separation agreement reached.
Zivo Bioscience appoints BDO as auditor and finalizes CEO John Payne's employment contract
Appointed BDO USA, LLP as independent auditor effective February 10, 2022, replacing resigned auditor Wolinetz, Lafazan & Company.
ZIVO Bioscience terminates CEO Andrew Dahl; Chairman John Payne named President and CEO
Andrew A. Dahl terminated as President and CEO on January 4, 2022.
On July 11, 2024, the Board of Directors of ZIVO Bioscience Inc., (the “Company”) increased its size from four (4) to five (5) members and appointed Laith Yaldoo to fill the vacancy.
The Company reaffirms that the Board terminated Dahl for cause.
on February 18, 2022, Mr. Dahl resigned from his position as a member of the Company’s board of directors.
the Company terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.
Effective as of January 7, 2022, the Board of the Company appointed Mr. John B. Payne as the Company’s President and Chief Executive Officer.
On January 4, 2022, Zivo Bioscience, Inc. (the “Company” ) terminated the employment of Andrew A. Dahl, the President and Chief Executive Officer of the Company.
On September 16, 2021, Mr. Rondeau gave notice of his intent to resign from the Board of Directors (the “Board”) of Zivo Bioscience, Inc. (the “Company”) effective on September 17, 2021.
Max materiality 0.85 · Median 0.50 · Most common event other_material